FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS
Provided are methods and compositions for the delivery of fully human post-translationally modified therapeutic monoclonal antibodies and antigen-binding fragments thereof. The fully human post-translationally modified therapeutic monoclonal antibodies may be delivered by gene therapy methods, e.g.,...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | DANOS, Olivier GERNER, Franz MCDOUGALD, Devin EVEREN, Sherri, Van QIAO, Chunping WU, Zuchun GLENN, Justin BRUDER, Joseph LIU, Ye WANG, Xu |
| description | Provided are methods and compositions for the delivery of fully human post-translationally modified therapeutic monoclonal antibodies and antigen-binding fragments thereof. The fully human post-translationally modified therapeutic monoclonal antibodies may be delivered by gene therapy methods, e.g., as a recombinant adeno-associated vims (rAAV) vector to the appropriate tissue. Methods of manufacture of the AAV vectors, pharmaceutical compositions and methods of treatment are also provided. In addition, provided are methods of producing therapeutic antibodies that are "biobetters" as fully human post-translationally modified. These fully human post-translationally modified therapeutic antibodies may be administered to a subject in need of treatment with the therapeutic antibody. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP3959323A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP3959323A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP3959323A13</originalsourceid><addsrcrecordid>eNrjZLB3C_XxidT1CPV19FMI8A8O0Q0JcvQL9nEM8fT3cwRKKfj6u3i6ebq6KDj6hXg6-btEKoR4uAY5BriGhng6B_MwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUknjXAGNLU0tjI2NHQ2MilAAAefMqpA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS</title><source>esp@cenet</source><creator>DANOS, Olivier ; GERNER, Franz ; MCDOUGALD, Devin ; EVEREN, Sherri, Van ; QIAO, Chunping ; WU, Zuchun ; GLENN, Justin ; BRUDER, Joseph ; LIU, Ye ; WANG, Xu</creator><creatorcontrib>DANOS, Olivier ; GERNER, Franz ; MCDOUGALD, Devin ; EVEREN, Sherri, Van ; QIAO, Chunping ; WU, Zuchun ; GLENN, Justin ; BRUDER, Joseph ; LIU, Ye ; WANG, Xu</creatorcontrib><description>Provided are methods and compositions for the delivery of fully human post-translationally modified therapeutic monoclonal antibodies and antigen-binding fragments thereof. The fully human post-translationally modified therapeutic monoclonal antibodies may be delivered by gene therapy methods, e.g., as a recombinant adeno-associated vims (rAAV) vector to the appropriate tissue. Methods of manufacture of the AAV vectors, pharmaceutical compositions and methods of treatment are also provided. In addition, provided are methods of producing therapeutic antibodies that are "biobetters" as fully human post-translationally modified. These fully human post-translationally modified therapeutic antibodies may be administered to a subject in need of treatment with the therapeutic antibody.</description><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220302&DB=EPODOC&CC=EP&NR=3959323A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220302&DB=EPODOC&CC=EP&NR=3959323A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DANOS, Olivier</creatorcontrib><creatorcontrib>GERNER, Franz</creatorcontrib><creatorcontrib>MCDOUGALD, Devin</creatorcontrib><creatorcontrib>EVEREN, Sherri, Van</creatorcontrib><creatorcontrib>QIAO, Chunping</creatorcontrib><creatorcontrib>WU, Zuchun</creatorcontrib><creatorcontrib>GLENN, Justin</creatorcontrib><creatorcontrib>BRUDER, Joseph</creatorcontrib><creatorcontrib>LIU, Ye</creatorcontrib><creatorcontrib>WANG, Xu</creatorcontrib><title>FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS</title><description>Provided are methods and compositions for the delivery of fully human post-translationally modified therapeutic monoclonal antibodies and antigen-binding fragments thereof. The fully human post-translationally modified therapeutic monoclonal antibodies may be delivered by gene therapy methods, e.g., as a recombinant adeno-associated vims (rAAV) vector to the appropriate tissue. Methods of manufacture of the AAV vectors, pharmaceutical compositions and methods of treatment are also provided. In addition, provided are methods of producing therapeutic antibodies that are "biobetters" as fully human post-translationally modified. These fully human post-translationally modified therapeutic antibodies may be administered to a subject in need of treatment with the therapeutic antibody.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB3C_XxidT1CPV19FMI8A8O0Q0JcvQL9nEM8fT3cwRKKfj6u3i6ebq6KDj6hXg6-btEKoR4uAY5BriGhng6B_MwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUknjXAGNLU0tjI2NHQ2MilAAAefMqpA</recordid><startdate>20220302</startdate><enddate>20220302</enddate><creator>DANOS, Olivier</creator><creator>GERNER, Franz</creator><creator>MCDOUGALD, Devin</creator><creator>EVEREN, Sherri, Van</creator><creator>QIAO, Chunping</creator><creator>WU, Zuchun</creator><creator>GLENN, Justin</creator><creator>BRUDER, Joseph</creator><creator>LIU, Ye</creator><creator>WANG, Xu</creator><scope>EVB</scope></search><sort><creationdate>20220302</creationdate><title>FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS</title><author>DANOS, Olivier ; GERNER, Franz ; MCDOUGALD, Devin ; EVEREN, Sherri, Van ; QIAO, Chunping ; WU, Zuchun ; GLENN, Justin ; BRUDER, Joseph ; LIU, Ye ; WANG, Xu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP3959323A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2022</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>DANOS, Olivier</creatorcontrib><creatorcontrib>GERNER, Franz</creatorcontrib><creatorcontrib>MCDOUGALD, Devin</creatorcontrib><creatorcontrib>EVEREN, Sherri, Van</creatorcontrib><creatorcontrib>QIAO, Chunping</creatorcontrib><creatorcontrib>WU, Zuchun</creatorcontrib><creatorcontrib>GLENN, Justin</creatorcontrib><creatorcontrib>BRUDER, Joseph</creatorcontrib><creatorcontrib>LIU, Ye</creatorcontrib><creatorcontrib>WANG, Xu</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DANOS, Olivier</au><au>GERNER, Franz</au><au>MCDOUGALD, Devin</au><au>EVEREN, Sherri, Van</au><au>QIAO, Chunping</au><au>WU, Zuchun</au><au>GLENN, Justin</au><au>BRUDER, Joseph</au><au>LIU, Ye</au><au>WANG, Xu</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS</title><date>2022-03-02</date><risdate>2022</risdate><abstract>Provided are methods and compositions for the delivery of fully human post-translationally modified therapeutic monoclonal antibodies and antigen-binding fragments thereof. The fully human post-translationally modified therapeutic monoclonal antibodies may be delivered by gene therapy methods, e.g., as a recombinant adeno-associated vims (rAAV) vector to the appropriate tissue. Methods of manufacture of the AAV vectors, pharmaceutical compositions and methods of treatment are also provided. In addition, provided are methods of producing therapeutic antibodies that are "biobetters" as fully human post-translationally modified. These fully human post-translationally modified therapeutic antibodies may be administered to a subject in need of treatment with the therapeutic antibody.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP3959323A1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
| title | FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T21%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DANOS,%20Olivier&rft.date=2022-03-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP3959323A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |